45 results on '"MacCabe A"'
Search Results
2. Schizophrenia polygenic risk predicts general cognitive deficit but not cognitive decline in healthy older adults
3. Schizophrenia polygenic risk predicts general cognitive deficit but not cognitive decline in healthy older adults
4. Association of polygenic liabilities for schizophrenia and bipolar disorder with educational attainment and cognitive aging.
5. Blood metabolites, neurocognition and psychiatric disorders: a Mendelian randomization analysis to investigate causal pathways.
6. Pharmacogenomic scores in psychiatry: systematic review of current evidence.
7. Towards a scalable approach to assess speech organization across the psychosis-spectrum -online assessment in conjunction with automated transcription and extraction of speech measures.
8. Development of an individualized risk calculator of treatment resistance in patients with first-episode psychosis (TRipCal) using automated machine learning: a 12-year follow-up study with clozapine prescription as a proxy indicator.
9. Differences in white blood cell proportions between schizophrenia cases and controls are influenced by medication and variations in time of day.
10. Machine learning methods to predict outcomes of pharmacological treatment in psychosis.
11. Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study.
12. Heterogeneity in treatment outcomes and incomplete recovery in first episode psychosis: does one size fit all?
13. The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia.
14. Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.
15. Hippocampal circuit dysfunction in psychosis.
16. Childhood maltreatment mediates the effect of the genetic background on psychosis risk in young adults.
17. Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis.
18. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.
19. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.
20. Drinking and smoking polygenic risk is associated with childhood and early-adulthood psychiatric and behavioral traits independently of substance use and psychiatric genetic risk.
21. A systematic review and meta-analysis of the association between maternal polycystic ovary syndrome and neuropsychiatric disorders in children.
22. Screening for pathogenic neuronal autoantibodies in serum and CSF of patients with first-episode psychosis.
23. Neuroinflammation in schizophrenia: the role of nuclear factor kappa B.
24. Sex-specific effects of polygenic risk for schizophrenia on lifespan cognitive functioning in healthy individuals.
25. Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review.
26. Differential dopamine release by psychosis-generating and non-psychosis-generating addictive substances in the nucleus accumbens and dorsomedial striatum.
27. Characterising the shared genetic determinants of bipolar disorder, schizophrenia and risk-taking.
28. Cost effectiveness of pharmacogenetic-guided clozapine administration based on risk of HLA variants in Japan and the UK.
29. Assessing olfactory, memory, social and circadian phenotypes associated with schizophrenia in a genetic model based on Rim.
30. Resting-state dopaminergic cell firing in the ventral tegmental area negatively regulates affiliative social interactions in a developmental animal model of schizophrenia.
31. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry.
32. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits.
33. Multiple variants aggregate in the neuregulin signaling pathway in a subset of schizophrenia patients.
34. The effects of polygenic risk for psychiatric disorders and smoking behaviour on psychotic experiences in UK Biobank.
35. Mesenchymal stem cells derived extracellular vesicles improve behavioral and biochemical deficits in a phencyclidine model of schizophrenia.
36. Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics.
37. Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients.
38. The genetic relationship between educational attainment and cognitive performance in major psychiatric disorders.
39. Dynamic expression of genes associated with schizophrenia and bipolar disorder across development.
40. Sex difference in association of symptoms and white matter deficits in first-episode and drug-naive schizophrenia.
41. Elevated allostatic load early in the course of schizophrenia.
42. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.
43. Review of withdrawal catatonia: what does this reveal about clozapine?
44. Polygenic pleiotropy and potential causal relationships between educational attainment, neurobiological profile, and positive psychotic symptoms.
45. Herpes simplex virus 1 infection on grey matter and general intelligence in severe mental illness
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.